Daily Sepsis Research Analysis
Analyzed 43 papers and selected 3 impactful papers.
Summary
Three high-impact sepsis studies advance mechanistic and translational understanding: (1) Science identifies platelet-derived integrin- and tetraspanin-enriched tethers (PITTs) that amplify inflammation and correlate with severity in sepsis; (2) Nature Communications shows that neutralizing truncated procalcitonin preserves endothelial integrity and reduces sepsis severity in vivo; (3) Multi-omics Mendelian randomization pinpoints TBCB as a causal, druggable target for sepsis-induced liver injury with in vivo/in vitro validation.
Research Themes
- Platelet-driven immunothrombosis and inflammatory amplification in sepsis
- Endothelial protection by targeting truncated procalcitonin
- Genetic causal inference identifies TBCB as a therapeutic target in sepsis-induced liver injury
Selected Articles
1. Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation.
This study identifies PITTs as proinflammatory platelet membrane structures that anchor to leukocytes/endothelium, promoting leukocyte activation and vascular inflammation. In mouse infection/endotoxemia models, αIIbβ3 blockade reduced immune-mediated tissue damage; in human sepsis/COVID-19, PITT formation and platelet αIIbβ3 loss correlated with disease severity.
Impact: Reveals a previously unrecognized platelet-derived inflammatory structure linking thrombosis and inflammation with direct relevance to sepsis severity, suggesting αIIbβ3/PITT as a therapeutic axis.
Clinical Implications: αIIbβ3 antagonism or strategies that prevent PITT formation may attenuate thrombo-inflammation in sepsis. PITT levels could serve as biomarkers for risk stratification and therapeutic monitoring.
Key Findings
- Flow-triggered αIIbβ3 ligation induces PITTs that tether to leukocytes/endothelium while platelet bodies detach.
- PITTs promote leukocyte activation and vascular inflammation in mouse infection/endotoxemia models.
- αIIbβ3 blockade reduces immune-mediated tissue damage in vivo.
- In patients with sepsis/COVID-19/severe infection, higher PITT formation and αIIbβ3 loss correlate with worse outcomes.
Methodological Strengths
- Mechanistic in vivo models complemented by human correlative data.
- Use of flow-based assays to recapitulate physiological shear conditions and ligand-specific αIIbβ3 engagement.
Limitations
- Clinical cohorts are correlative; causality in humans remains to be established.
- Potential bleeding risks with αIIbβ3 blockade require careful translational consideration.
Future Directions: Prospective human studies to validate PITTs as biomarkers; interventional trials of αIIbβ3/PITT-targeted therapies; deeper characterization of PITT composition and clearance.
Platelet integrin αIIbβ3 is essential for hemostasis, thrombosis, and inflammation. We found that ligation of αIIbβ3 by von Willebrand factor or fibrin under flow triggered its accumulation in plasma membrane extensions or "platelet-derived integrin- and tetraspanin-enriched tethers" (PITTs). PITTs remained anchored to leukocytes or endothelial cells, whereas the partially αIIbβ3-deficient platelet body detached. Although still responsive to stimuli, αIIbβ3-deficient platelets did not support thrombus
2. Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin.
Neutralizing truncated procalcitonin in murine sepsis halves endothelial transcriptomic perturbations, preserves vascular barrier integrity, mitigates vasoplegia, and improves organ integrity and sepsis severity. Mechanistically, procalcitonin neutralization is associated with reduced interleukin-17 pathway signaling.
Impact: Identifies a druggable upstream mediator of endothelial dysfunction in sepsis and demonstrates functional vascular and organ protection with antibody neutralization.
Clinical Implications: Anti-procalcitonin strategies could complement current sepsis care by stabilizing endothelium and microcirculation, warranting translational studies and early-phase trials.
Key Findings
- Sepsis induces >2000 proinflammatory endothelial gene changes and downregulates growth/maintenance programs.
- Anti-procalcitonin antibody reduces endothelial transcriptomic perturbations by >50% and preserves lung/intestine barrier integrity.
- Neutralization mitigates vasoplegia, preserves endothelial NO bioavailability, improves organ integrity, and reduces sepsis severity in mice.
- Mechanistic link to reduced IL-17 pathway signaling after procalcitonin neutralization.
Methodological Strengths
- Endothelial transcriptomics integrated with functional vascular assays and organ-level outcomes.
- Mechanistic pathway linkage (IL-17) supports causality beyond phenotypic observations.
Limitations
- Preclinical murine models; human efficacy and safety of procalcitonin neutralization remain untested.
- Antibody specificity and off-target vascular effects require careful evaluation.
Future Directions: Biomarker-guided patient stratification (truncated procalcitonin levels), dose-finding and safety studies in humans, and combination strategies with vasopressors or anticoagulation.
Sepsis is associated with hypotension, vascular leakage, vasoplegia and microvascular dysfunction. Therefore, the endothelium is a target for sepsis therapies. Since truncated procalcitonin exerts vascular activity, we here evaluated the efficacy of targeting procalcitonin for vascular integrity and sepsis outcomes. Sepsis up-regulated >2000 genes involved in pro-inflammatory responses while similar numbers of genes involving cell growth and maintenance were down-regulated. Transcriptomic changes in
3. Multi-omics analysis identifies TBCB as a therapeutic target in sepsis-induced liver injury.
Integrating proteome-wide and expression MR with sepsis GWAS prioritized TBCB as a causal protein for sepsis, particularly in liver injury. TBCB was upregulated in vivo/in vitro models, and its knockdown attenuated inflammatory signaling, implicating intracellular lipid metabolism/homeostasis; docking suggested small-molecule modulators.
Impact: Provides causal genetic evidence converging with experimental validation to nominate a new, mechanistically anchored therapeutic target for sepsis-induced liver injury.
Clinical Implications: TBCB inhibition could represent a novel strategy to mitigate sepsis-induced liver injury; findings justify medicinal chemistry and early translational development.
Key Findings
- Proteome-wide and expression MR across large cohorts identified TBCB as a causal candidate in sepsis.
- TBCB expression is significantly upregulated during sepsis-induced liver injury in vivo and in vitro.
- TBCB knockdown attenuates inflammatory signaling and modulates intracellular lipid metabolism/homeostasis.
- Molecular docking and dynamics predict small molecules that bind TBCB, indicating druggability.
Methodological Strengths
- Two-stage, multi-omics causal inference (pQTL/eQTL MR) integrated with GWAS signals.
- Orthogonal validation in vivo and in vitro strengthens mechanistic plausibility.
Limitations
- MR estimates reflect lifetime genetic exposure; pharmacologic modulation effects may differ.
- Functional work focused on liver; systemic effects and off-targets need broader evaluation.
Future Directions: Medicinal chemistry to optimize TBCB binders, target validation in additional organs and species, and preclinical efficacy/safety profiling.
BACKGROUND: This study aimed to identify potential therapeutic targets for sepsis and elucidate the underlying molecular mechanisms, with a particular focus on the liver as a key target organ for experimental validation. METHODS: Here, two sequential studies were conducted to uncover and characterize therapeutic targets involved in sepsis-induced liver injury. In Study 1, a proteome-wide Mendelian randomization (MR) analysis was performed using protein quantitative trait loci from deCODE (n = 35 559 Icelanders), UK Biobank (n = 54 219), ARIC (n = 7213 Europ